Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL

  • days left to enroll
  • participants needed
  • sponsor
    Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Updated on 11 April 2021
lymphoid leukemia
ejection fraction
consolidation therapy


To evaluate the safety and efficacy of CD19/CD22 Bispecific CAR-T for the treatment of MRD-positive B cell acute lymphoblastic leukemia. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19/CD22 CAR+ T cells.


Participants with MRD-positive B cell acute lymphoblastic leukemia can participate if all eligibility criteria are met. Tests required to determine eligibility include disease assessments, a physical exam, Electrocardiograph, CT/MRI , and blood draws. Participants receive chemotherapy prior to the infusion of CD19/CD22 CAR+ T cells. After the infusion, participants will be followed for side effects and effect of CD19/CD22 CAR+ T cells. Study procedures may be performed while hospitalized.

Condition childhood ALL, Lymphocytic Leukemia, Acute, MRD-positive, acute lymphoblastic leukemia, leukemia, acute lymphoblastic, acute lymphoid leukaemia, acute lymphocytic leukemia, acute lymphoblastic leukemia (all), MRD-positive, MRD-positive, MRD-positive
Treatment cyclophosphamide, Fludarabine, anti-CD19/CD22 CAR-T cells
Clinical Study IdentifierNCT03919526
SponsorShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Last Modified on11 April 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 70 yrs?
Gender: Male or Female
Do you have any of these conditions: childhood ALL or MRD-positive?
Do you have any of these conditions: acute lymphoblastic leukemia or acute lymphoid leukaemia or acute lymphocytic leukemia or childhood ALL or leukemia, acute lymphoblastic or MRD-positi...?
Do you have any of these conditions: acute lymphocytic leukemia or MRD-positive or acute lymphoid leukaemia or childhood ALL or acute lymphoblastic leukemia or acute lymphoblastic leukemi...?
Do you have any of these conditions: acute lymphoblastic leukemia or acute lymphocytic leukemia or childhood ALL or acute lymphoblastic leukemia (all) or MRD-positive or Lymphocytic Leuke...?
(1) CD19 positive/CD22 positive, or CD19-CD22 positive B-cell acute lymphoblastic leukemia
(2)18 to 70 Years Old, Male and female
(3) Expected survival > 12 weeks
(4) ECOG score 0-2
(5) Bone marrow examination clearly diagnosed as B-cell acute lymphoblastic leukemia and who met one of the following conditions
Recurrent patients who achieves MRD-positive CR or CRi after standard therapy
Those who achieves CR, but failed to achieve MRD-negative after at least 2 courses of consolidation therapy
(6) The venous access required for collection can be established and mononuclear cell collection can be determined by the investigators
(7) Liver, kidney and cardiopulmonary functions meet the following requirements
Creatinine is in the normal range
Left ventricular ejection fraction >50%
Baseline oxygen saturation>92%
Total bilirubin 2ULN
ALT and AST 2.5ULN
(8) Able to understand and sign the Informed Consent Document

Exclusion Criteria

(1) BCR-ABL fusion gene-positive patients
(2) Malignant tumors other than acute lymphoblastic leukemia within 5 years prior to screening, in addition to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, and ductal carcinoma in situ after radical resection
(3) Subjects with positive HBsAg or HBcAb and peripheral blood HBV DNA titer detection 1 102 copy number / L; HCV antibody positive and peripheral blood HCV RNA positive; HIV antibody positive; CMV DNA positive; syphilis positive
(4) Any instability of systemic disease, including but not limited to unstable angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification III), need drug therapy of severe arrhythmia, liver, kidney, or metabolic disease
(5) Active or uncontrollable infection requiring systemic therapy within 14 days prior to enrollment
(6) Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1 year after cell transfusion, or male subject whose partner plans to have a pregnancy within 1 year after cell transfusion
(7) Received CAR-T treatment or other gene therapies before enrollment
(8) Patients with symptoms of central nervous system
(9) Subjects who are receiving systemic steroid treatment and requiring long-term systemic steroid treatment during the treatment as determined by the investigator before screening (except inhalation or topical use); And subjects treated with systemic steroids (except inhalation or topical use) within 72h prior to cell transfusion
(10) The investigators consider other conditions unsuitable for enrollment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note